Biocon Ltd.

Most investors who looked at Biocon between 2022 and early 2025 came away with a mixed read. Revenues were growing, but net profit margins were under pressure. The acquisition of Viatris' global biosimilars business, announced in February 2022 and closed in November that year, brought a significant debt load. Finance charges, higher depreciation and expanded manufacturing infrastructure, and integration expenses across 120 countries compressed the bottom line even as operating performance improved. The business remained profitable throughout, but reported net margins were thin and the stock drifted sideways as the market struggled to see through the transition costs.[EasyDNNnews:PaidContentStart]

What the reading missed was the nature of what was being built. The acquisition was not just a distribution deal. It was a structural transformation of how Biocon earned from its own molecules. The integration costs were the price of moving from a manufacturer sharing economics with a commercial partner to a company that owns the full value chain from development to patient.

About the Company
Biocon Limited is India's largest biopharmaceutical company, founded in 1978 in Bangalore by Kiran Mazumdar-Shaw. Starting as an enzyme manufacturer, it pivoted into pharmaceuticals and built one of the most comprehensive biosimilar portfolios in the world. That pivot, spanning decades of capital allocation and regulatory effort, is the foundation of everything that makes Biocon interesting to investors today. The company operates three businesses.

Biocon Biologics: Biosimilars
Biological medicines are derived from living cells and treat serious conditions including cancer, autoimmune diseases, and diabetes. A biosimilar is a clinically validated, lower-cost version developed after the original patent expires, requiring scientific depth, large-scale manufacturing, and rigorous regulatory approval. Biocon Biologics has spent two decades building this capability. It has 12 biosimilars commercialised across more than 120 countries, serving over 6.5 million patients annually.

In FY26, the segment generated ₹10,431 crore in revenue, up 16 per cent year on year, with an EBITDA margin of 26 per cent, making it the clear engine of the consolidated business. Revenue growth was 19 per cent year on year and the segment contributed 60 per cent of the total company revenue.

Generics: APIs and Formulations
The Generics business manufactures pharmaceutical ingredients and finished formulations for global markets. It contributed ₹3,168 crore in FY26, up 17 per cent year on year on a comparable basis, with an EBITDA margin of 5 per cent, driven by U.S. and European launches including generic Lenalidomide, Dasatinib, and the Sacubitril and Valsartan combination used for heart failure. The segment contributed 18 per cent of the total company revenue.

CRDMO: Syngene International
Syngene serves global pharma and biotech companies that outsource research and manufacturing work. It contributed ₹3,739 crore in FY26, up 3 per cent year on year, with EBITDA margins stable at 26 per cent. It is the stabiliser in Biocon's financial mix, capital-light and consistently profitable. The segment contributed 22 per cent of total FY26 revenue.

The Acquisition That Reshaped Biocon
For most of its history, Biocon depended on Viatris to commercialise its biosimilars in the U.S. and Europe. Viatris ran sales teams, managed hospital relationships, and shared a portion of profits back with Biocon after deducting commercial costs. At the time of the deal, Viatris' biosimilars business generated estimated revenue of USD 1.1 billion with an EBITDA margin of roughly 23 per cent for CY23. Biocon's share came out of that already compressed number.

In February 2022, Biocon acquired Viatris' entire global biosimilars business for USD 3.335 billion, bringing full ownership of commercial operations across the U.S., Europe, and 120 countries, with every dollar of biosimilar revenue now flowing directly to Biocon.

The short-term cost was real: a USD 1.2 billion debt load, higher finance charges and depreciation, and exceptional items spread across FY23 to FY25. But biosimilar revenue grew from ₹3,464 crore in FY22 to ₹10,431 crore in FY26. Every biosimilar launched from now on no longer needs a new sales force or distribution network. That infrastructure is built and paid for, and that is where the margin expansion story begins.

The Viatris chapter closed in December 2025, when Biocon acquired the residual stake held by Mylan Inc. in Biocon Biologics for USD 815 million, structured as USD 400 million in cash and USD 415 million through a share swap. Biocon raised ₹4,150 crore through a Qualified Institutions Placement in January 2026 to fund the cash component. FY27 will be the first clean year to measure this business on its own terms.

Alongside the Viatris integration, Biocon divested its Formulations India business in two phases: the dermatology and nephrology units were sold to Eris Lifesciences in Q2FY24, and the remaining brands followed in Q3FY25, for a total transaction value of ₹1,242 crore. Investors reading the numbers without this context will have missed the underlying momentum.

Strategic Positioning: What Biocon Has Built
Most Indian pharma companies face the same bottleneck: they can manufacture, but they cannot commercialise in the U.S. and Europe at scale without a partner. Biocon solved that problem through the Viatris acquisition. It now owns a direct commercial presence across 120 countries, negotiating with hospital formularies, pharmacy benefit managers, and payers on its own terms. That infrastructure, once built, becomes the launchpad for every molecule in the pipeline without incurring the cost of building it again.

The pipeline is one of the broadest in the global biosimilars industry. With 12 biosimilars already commercialised and over 20 assets in development across therapeutic categories, Biocon's commercial depth is significant. In April 2025, it launched biosimilar Denosumab in the U.S. under the brand names Gnula and Gnulva, becoming the first company to launch an interchangeable biosimilar for both Prolia, for osteoporosis, and Xgeva, for bone complications in cancer patients, simultaneously. These three reference drugs recorded combined 2024 global sales of approximately USD 40.5 billion.

Financial Performance
FY26 was the year the operating machine became visible. Full-year operating revenue grew 13 per cent to ₹16,927 crore on a comparable basis, with total income at ₹17,270 crore, up 14 per cent. EBITDA grew 25 per cent to ₹3,798 crore, with margins expanding 200 basis points to 22 per cent. Net profit before exceptional items surged 323 per cent to ₹436 crore, while reported net profit stood at ₹386 crore. At the biosimilars level, the EBITDA margin reached 26 per cent, up from 22 per cent in FY25. The quarterly revenue trajectory was consistent across all four quarters of the year.

On the balance sheet, pro forma net debt at the biosimilars level stood at approximately USD 1.24 billion for the nine months ended December 31, 2025, with net debt to EBITDA at 2.8 times. Management noted at the Q4FY26 earnings call that FY27 performance should improve progressively as new products scale up meaningfully in the second half of the year.

Risks Worth Watching
Pricing erosion in mature biosimilar categories, particularly insulin biosimilars, will continue to pressure realisations. The pipeline molecules including Keytruda and Opdivo are among the most commercially promising in the plan, but the debt taken from the Viatris acquisition, though being actively reduced, remains a watch item, and any regulatory delay in key approvals can shift revenue timelines. ICRA, in its October 2025 rating review, noted that increasing competition and pricing pressure remain ongoing concerns. Currency risk also deserves mention: a substantial portion of revenue is denominated in U.S. dollars and euros, making consolidated rupee earnings sensitive to exchange rate movements.

The Road Ahead and Valuation
Biocon enters FY27 in a fundamentally different position from three years ago. The integration costs that obscured earnings are behind it. The commercial infrastructure across 120 countries is fully owned and operational, ready to absorb new launches without proportional cost increases. Biosimilar Denosumab has been launched in the U.S., generic Lenalidomide is commercialising, generic Semaglutide filings are progressing, and three high-value oncology biosimilars are in development targeting a combined reference drug market exceeding USD 40 billion.

Biocon should not be valued like a mature Dividend payer or a plain-vanilla pharma exporter. The investment case is built on operating and financial leverage from a fully integrated biosimilars platform, not on income. The dividend yield of 0.15 per cent is a token return and does not drive the thesis.

The key variable is whether FY27 begins to show cleaner earnings from that integrated platform. If it does, the market should attach greater value to the recurring commercial base. For investors already holding, the integration overhang has lifted. For those looking to enter, waiting two to three quarters for earnings clarity is the more prudent approach.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]